Keryx Biopharmaceuticals Announces Pricing of Public Offering of Common Stock

Keryx Biopharmaceuticals Announces Pricing of Public Offering of Common Stock

PR Newswire

NEW YORK, Jan. 30, 2013

NEW YORK, Jan.30, 2013 /PRNewswire/ --Keryx Biopharmaceuticals, Inc.
(NASDAQ: KERX) today announced the pricing of its previously announced
underwritten public offering of common stock consisting of 8,234,000 shares at
$8.49 per share. In connection with this offering, Keryx granted to the
underwriters a 30-day option to purchase  1,235,100 additional shares of
common stock. We intend to use the net proceeds from the sale of our common
stock to fund pre-launch/launch inventory build-up and select
pre-commercial/commercial activities related to Zerenex, and other general
corporate purposes.

J.P. Morgan Securities LLC is acting as sole book-running manager in the
offering. The co-managers for the offering are Barclays Capital Inc.,
Citigroup, Oppenheimer & Co. Inc., Stifel Nicolaus Weisel, JMP Securities LLC,
Roth Capital Partners, LLC, Brean Capital, LLC and Ladenburg Thalmann & Co.
Inc. Burrill Securities LLC, Dawson James Securities, Inc., Maxim Group LLC,
MLV & Co. LLC and Trout Capital LLC are acting as advisors to the company.

The securities described above are being offered by Keryx pursuant to a Form
S-3 shelf registration statement (including a base prospectus) previously
filed with the Securities and Exchange Commission ("SEC"). Before you invest,
you should read the prospectus in the registration statement and related
prospectus supplement that Keryx has filed with the SEC for more complete
information about Keryx and this offering. The prospectus supplement is
available for free by visiting EDGAR on the SEC's website located at
www.sec.gov. Copies of the prospectus supplement and accompanying prospectus
may also be obtained from the offices of J.P. Morgan Securities LLC, c/o
Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, New York
11717 (telephone: 866-803-9204).

This news release shall not constitute an offer to sell or the solicitation of
an offer to buy these securities, nor will there be any sale of these
securities in any state or other jurisdiction in which such offer,
solicitation or sale would be unlawful prior to the registration or
qualification under the securities laws of any such state or other
jurisdiction.

About Keryx Biopharmaceuticals, Inc.

Keryx Biopharmaceuticals is focused on the acquisition, development and
commercialization of medically important pharmaceutical products for the
treatment of renal disease. Keryx is developing Zerenex (ferric citrate), an
oral, ferric iron-based compound that has the capacity to bind to phosphate
and form non-absorbable complexes. Zerenex has completed a U.S.-based Phase 3
clinical program for the treatment of hyperphosphatemia (elevated phosphate
levels) in patients with end-stage renal disease, conducted pursuant to a
Special Protocol Assessment (SPA) agreement with the FDA, and Keryx expects to
submit an NDA with the FDA and a MAA with the EMA in the second quarter of
2013. Zerenex is also in Phase 2 development in the U.S. for the management
of phosphorus and iron deficiency in anemic patients with Stage 3 to 5
non-dialysis dependent chronic kidney disease. In addition, Keryx's Japanese
partner, Japan Tobacco Inc. and Torii Pharmaceutical Co., Ltd. has filed its
New Drug Application for marketing approval of ferric citrate in Japan for the
treatment of hyperphosphatemia in patients with chronic kidney disease. Keryx
is headquartered in New York City.

KERYX CONTACT:
Lauren Fischer
Director - Investor Relations
Keryx Biopharmaceuticals, Inc.
Tel: 212.531.5965
E-mail: lfischer@keryx.com

SOURCE Keryx Biopharmaceuticals, Inc.
 
Press spacebar to pause and continue. Press esc to stop.